Targeted Oncologic Therapies Demand New Approach to Phase II/III Trials
Executive Summary
Targeted cancer therapies should be studied in large Phase II programs that incorporate biomarkers, a panelist said at the annual meeting of the American Society of Clinical Oncology in Orlando, Fla
You may also be interested in...
Better, Faster, Smaller: Personalized Medicine Could Bring R&D Savings
PHILADELPHIA - One near-term benefit of adopting a personalized medicine approach to drug development would be a lower cost for clinical trials by conducting smaller, faster studies that will produce better results and help companies make go/ no go decisions sooner, according to speakers at the Wharton Health Care Business Conference
Better, Faster, Smaller: Personalized Medicine Could Bring R&D Savings
PHILADELPHIA - One near-term benefit of adopting a personalized medicine approach to drug development would be a lower cost for clinical trials by conducting smaller, faster studies that will produce better results and help companies make go/ no go decisions sooner, according to speakers at the Wharton Health Care Business Conference
Key To Better Oncology Trials Could Be Better Historical Controls, Study Says
The solution to poor clinical trial design in oncology trials could be better calculation of historical control rates used to create response measures, according to a study appearing in Clinical Cancer Research